[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634482":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":19,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":19,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"mccRCC","EXPERIMENTAL",[12],"Radiation: PETCT-guided radiation therapy",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","PETCT-guided radiation therapy","PETCT-guided radiation therapy: All patients will undergo both FDG PET\u002FCT and CAIX PET\u002FCT. Radiotherapy will be planned and delivered based on the imaging findings, with the goal of achieving the most comprehensive feasible (all-site) coverage whenever appropriate.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Mingwei Ma","CONTACT","+86-13693556512","drmingweima@bjmu.edu.cn",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":19,"email":44},"Ronghui Yu","+86-10-83572075","kyc@bjmu.edu.cn",{"type":46,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100634482","caix-pet-ct-guided-radiation-therapy-in-ccrcc-100634482",false,"NCT07540260","CAIX PET\u002F CT Guided Radiation Therapy in CcRCC.","COSTAR-002","Inclusion Criteria:\n\nAdults (≥18 years) Histologically confirmed clear cell renal cell carcinoma Recurrent or metastatic disease Planned or ongoing first-line systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) Dual PET\u002FCT imaging available (FDG PET\u002FCT and CAIX-targeted PET\u002FCT) and eligible for radiotherapy planning Multidisciplinary assessment confirms radiotherapy is feasible to treat ≥75% of detectable lesions Able to provide written informed consent\n\nExclusion Criteria:\n\nUnable to receive stereotactic radiotherapy as planned Uncontrolled serious comorbidities or active infection Pregnant or breastfeeding Unable or unwilling to comply with study procedures and follow-up","ALL","18 Years",{"count":57,"type":58},70,"ESTIMATED","INTERVENTIONAL",[61],"NA","This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET\u002FCT imaging (FDG PET\u002FCT and a CAIX-targeted PET\u002FCT) to map disease sites. When feasible, PET\u002FCT-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR). Patients will be followed to evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events (planned enrollment: \\~70).",[64,65,66],"Radiation Therapy","Metastatic Renal Cancer","Recurrent Renal Cell Cancer",[68,65,66],"SBRT","2026-04-13",{"date":71,"type":72},"2026-04-20","ACTUAL",{"date":74,"type":72},"2025-11-01",{"date":76,"type":58},"2030-12-31",{"name":5,"class":6},1]